Bahriye Aktas
A5040331693- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Estrogen and related hormone effects
- Uterine Myomas and Treatments
- Cancer Immunotherapy and Biomarkers
- Cervical Cancer and HPV Research
- Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- Endometriosis Research and Treatment
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Metastasis and carcinoma case studies
- Cellular Mechanics and Interactions
- 3D Printing in Biomedical Research
- Medical Imaging Techniques and Applications
University Hospital Leipzig
2017-2025
Klinik für Frauenheilkunde
2012-2025
Leipzig University
2018-2024
Essen University Hospital
2014-2024
Izmir Institute of Technology
2024
King's College - North Carolina
2024
King's College London
2024
Guy's Hospital
2024
Center for HIV and Hepatogastroenterology
2024
Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie
2024
The persistence of circulating tumor cells (CTC) in breast cancer patients might be associated with stem cell like which have been suggested to the active source metastatic spread primary tumors. Furthermore, these also may undergo phenotypic changes, known as epithelial-mesenchymal transition (EMT), allows them travel site metastasis formation without getting affected by conventional treatment. Here we evaluated 226 blood samples 39 during a follow-up palliative chemo-, antibody - or...
The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define subset of patients who received endocrine therapy. We present 3-year data and concordance analysis (among biomarkers/RS).Central tumor bank established from (intermediate high-risk, locally human epidermal growth factor...
The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating prognostic value RS, Ki-67, and other traditional clinicopathological parameters. A central tumour bank was prospectively established within PlanB. Following an amendment, hormone receptor (HR)+ , RS ≤ 11 were...
To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) guide systemic in early breast cancer.Baseline postendocrine Ki67 (Ki67post) were evaluated centrally. In trial, all patients received exclusively ET: with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved nodes) entered control arm if RS...
Abstract Introduction The role of circulating tumor cells (CTCs) in blood primary breast cancer patients is still under investigation. We evaluated the incidence CTCs blood, we correlation between and disseminated (DTCs) bone marrow (BM), characterized for expression HER2, estrogen receptor (ER) progesterone (PR). Methods Blood 431 with were analyzed EpCAM, MUC1 HER2 transcripts AdnaTest BreastCancer ™ (AdnaGen AG, Germany). Expression ER PR was assessed an additional RT-PCR. BM aspirates...
Abstract Introduction There is a multitude of assays for the detection circulating tumor cells (CTCs) but very limited number studies comparing clinical relevance results obtained with different test methods. The DETECT trial metastatic breast cancer patients was designed to directly compare prognostic impact two commercially available CTC that are prominent representatives immunocytochemical and RT-PCR based technologies. Methods In total, 254 were enrolled in this prospective multicenter...
Purpose To test whether combining bevacizumab, an anti–vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET. Patients and Methods A multicenter, randomized, open-label, phase III, binational (Spain Germany) study added bevacizumab (15 mg/kg every 3 weeks) ET (ET-B; letrozole or fulvestrant) as first-line in postmenopausal patients human epidermal receptor 2 (HER2) –negative hormone receptor–positive advanced...
The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate compared with solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients primary breast cancer (BC). Here, we report data on long-term outcomes.Patients histologically confirmed BC were randomly assigned a 1:1 ratio to 12 times NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2) or...
Purpose Human epidermal growth factor receptor 2 (HER2)–positive/hormone (HR)–positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little known about the efficacy of combination endocrine therapy (ET) trastuzumab or potent antibody-cytotoxic, anti-HER2 compound emtansine (T-DM1) without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted...
PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment human epidermal growth factor receptor 2–negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more following: pT greater than 2, grade 2 3, high urokinase-type plasminogen activator/plasminogen activator...
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results higher pCR rates uncertain survival impact. We evaluated gemcitabine a backbone as short 12-week A-free focus on early response.Patients TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor 2-negative,...
Abstract BACKGROUND Platinum resistance constitutes one of the most recognized clinical challenges for ovarian cancer. Notably, detection primary tumor-based excision repair cross-complementation group 1 (ERCC1) protein by immunohistochemistry was recently shown to be inaccurate prediction platinum resistance. On basis previous finding that circulating tumor cells (CTC) in blood cancer patients are prognostically significant, and given our hypothesis negative prognostic impact CTC may arise...
Tissue, cell, and nucleus morphology change during tumor progression. In 2D confluent cell cultures, different tissue states, such as fluid (unjammed) solid (jammed), are correlated with shapes. These results do not have to apply a priori three dimensions. Cancer motility requires corresponds fluidization of the on bulk level. Here, we investigate fluidity in 3D determine how it correlates shape. patient samples mamma cervix carcinoma, find areas where cells can move or immobile. We compare...
•Final safety and efficacy results from PERUSE with ∼6 years' median follow-up are consistent CLEOPATRA results.•Results provide reassurance that paclitaxel is a valid alternative to docetaxel first-line pertuzumab trastuzumab.•In exploratory analyses, presence of both visceral disease prior trastuzumab identified subgroup worse PFS. BackgroundThe phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination pertuzumab, as standard therapy for...